Barriers to hepatitis C virus treatment in Guangdong Province

Xiaohua Yang1, Zhen Xu1, Yongyu Mei1

  • 1Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.

Insights

Many hepatitis C virus (HCV) patients in Guangdong do not receive antiviral therapy (AVT) due to cost, fear of side effects, and medical contraindications. Addressing these barriers is key to increasing HCV cure rates.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection remains a significant public health concern.
  • Chronic HCV infection requires effective antiviral therapy (AVT) to prevent severe liver disease.
  • Increasing HCV cure rates is a primary goal in Guangdong Province.

Purpose of the Study:

  • To analyze the reasons for non-treatment among HCV-infected patients.
  • To identify barriers to accessing antiviral therapy (AVT) for chronic hepatitis C.
  • To inform strategies for improving HCV treatment rates in Guangdong Province.

Main Methods:

  • A retrospective and prospective study was conducted.
  • The study cohort comprised 435 outpatients diagnosed with HCV infection.
  • Subjective and objective causes of non-treatment were analyzed.

Main Results:

  • Out of 1,931 patients, 435 did not receive AVT.
  • Key reasons for non-treatment included economic constraints (17.7%), patient fears (10.6%), fertility concerns (8.5%), and dosing inconvenience (2.1%).
  • Medical contraindications were prevalent (31.5%), including decompensated hepatic cirrhosis (12.6%), alcoholism (3.4%), and drug addiction (7.1%).

Conclusions:

  • HCV non-treatment is multifactorial, influenced by patient-related and medical factors.
  • Economic constraints and patient apprehension regarding side effects are significant barriers to AVT.
  • Medical contraindications, such as advanced liver disease and substance abuse, also limit treatment access.
Abstract